Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 9, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001159036-26-000014
Filed / recorded
Feb 12, 2026, 1:56 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HALOZYME THERAPEUTICS, INC.
Issuer CIK
1159036
Ticker
HALO
Reporting person
Helen Torley
Relationship
Director, Officer
Officer title
PRESIDENT AND CEO
Security
Performance Stock Units
Table
Derivative (Table II)
Transaction date
Feb 9, 2026
Transaction code
A
Shares / units
19,807
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
51,171
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
